Project Grant HT94252510268
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$426K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
The federal Project Grant award of $1,477,615.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. This research, conducted by the University of British Columbia, aims to transform healthcare for military service members, veterans, and the broader public through innovative and...
The University of British Columbia (UBC), through its Research Services division, has been awarded a $407,599 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 2-year research project titled "Epigenetic and Metabolomics Vulnerabilities in ASCL1-Driven NEPC Subtype" starting on September 1, 2024. This grant allows UBC researchers to leverage their expertise in biomedical research to...
The University of British Columbia (UBC) received a $507,035 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420). The grant, awarded on September 1, 2023, will fund research for "The Ovarian Cancer Observatory: Prevention, Impact, and Learning from Opportunistic Salpingectomy" over a 4-year period through August 31, 2027. As the prime grantee, UBC will leverage its expertise in medical research and data analysis...
The University of British Columbia (UBC), through its Research Services division, was awarded a $1,156,654 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research aimed at neuromodulation techniques to improve bladder function in a large animal model of spinal cord injury. The research will be conducted over a period of 3 years from September 30, 2024 to September 29, 2027. As a prominent...
The University of British Columbia (UBC) received a $1,731,421.95 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) to provide advanced physiologic monitoring at the site of spinal cord injury. The 3-year project, with a start date of September 30, 2023, will focus on transforming healthcare for Service Members and the public through innovative and impactful research into medical solutions for the battlefield. As the...
This $439,912 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Provincial Health Services Authority, operating as BC Cancer, a major Canadian healthcare organization specializing in cancer research, treatment, and prevention. The grant aims to "HARNESSING THE IMMUNE RESPONSE IN EXCEPTIONALLY LONG-TERM SURVIVORS TO DEVELOP NOVEL THERAPEUTICS", leveraging BC Cancer's expertise...
The University of British Columbia received a $1,259,331 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2024 targeting a non-oncogene addiction to the autocrine SEMA3C growth pathway for the treatment of lethal metastatic prostate cancer. A portion of the work involving confirming AR-V7 regulation of SEMA3C expression and...
The University of British Columbia was awarded a $2,498,328 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on using blood biomarkers to improve diagnosis of brain injury and assess dementia risk in survivors of intimate partner violence. The 4-year grant, awarded on June 1, 2024, will enable UBC researchers to leverage their expertise in biomedical research, clinical trials, and data analysis to...
The University of British Columbia (UBC) was awarded a $561,584 project grant by the Defense Health Agency to conduct research on the measurement and impact of body composition using CT imaging in patients with germ cell tumors undergoing chemotherapy. This grant is funded under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to transform healthcare for service members and the public through innovative and impactful research, including...